| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Zeylenone targets the PI3K/AKT/mTOR and MAPK/ERK signaling pathways, which are critical regulators of cell proliferation, survival, and apoptosis. By modulating these pathways, Zeylenone inhibits cancer cell proliferation and induces apoptosis in cervical carcinoma cells. The compound's mechanism of action involves interacting with specific molecular targets within these signaling cascades, leading to the suppression of tumor growth. Zeylenone's anti-inflammatory activity is also mediated through its effects on these and related signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, Zeylenone inhibits proliferation and induces apoptosis in cervical carcinoma cells via the PI3K/AKT/mTOR and MAPK/ERK pathways. The compound has good antitumor efficacy and exhibits antiproliferative activity. Zeylenone's in vitro activity has been demonstrated in various cancer cell lines, establishing its potential as an anticancer agent. The compound also exhibits anti-inflammatory properties in in vitro models. Further studies are needed to fully characterize its in vitro activity profile across different cancer types.
|
| ln Vivo |
Detailed in vivo activity data for Zeylenone are limited in publicly available literature. As a natural product with antitumor activity, Zeylenone is being investigated for its therapeutic potential in various cancer models. Its ability to modulate PI3K/AKT/mTOR and MAPK/ERK signaling pathways suggests that it may have efficacy in vivo against tumors that are dependent on these pathways. The compound's anti-inflammatory activity also suggests potential applications in inflammatory diseases. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
Zeylenone is a natural product and is not typically used in standard receptor binding assays. Its activity is assessed through cell-based assays measuring signaling pathway modulation. In these assays, cells are treated with Zeylenone at varying concentrations, and the phosphorylation status of key proteins in the PI3K/AKT/mTOR and MAPK/ERK pathways is assessed by Western blot. Cell viability and apoptosis are measured using standard assays such as MTT, flow cytometry for Annexin V staining, or caspase activity assays. The compound's effects on pathway modulation are correlated with its antiproliferative and pro-apoptotic activities.
|
| Cell Assay |
Cellular assays for Zeylenone are performed using cervical carcinoma cell lines or other cancer cell lines. Cells are cultured in appropriate media and treated with Zeylenone at varying concentrations for defined time periods. Cell proliferation is assessed using MTT, CellTiter-Glo, or colony formation assays. Apoptosis is assessed by measuring caspase activation, PARP cleavage, or Annexin V staining. The PI3K/AKT/mTOR and MAPK/ERK signaling pathways are assessed by Western blot analysis of phosphorylated proteins. The compound is typically dissolved in DMSO and diluted in cell culture media for treatment.
|
| Animal Protocol |
In vivo studies with Zeylenone are conducted in mouse xenograft models using cancer cell lines. Zeylenone is administered via appropriate routes (e.g., intraperitoneal or oral) at defined doses and schedules. Tumor growth is monitored by caliper measurements, and tumor volumes are calculated. Tumor tissues are collected for histological analysis and assessment of signaling pathway modulation by immunohistochemistry or Western blot. Pharmacokinetic parameters may be determined from plasma samples collected at various time points. Further studies are needed to fully characterize the in vivo efficacy of Zeylenone.
|
| ADME/Pharmacokinetics |
Zeylenone has a molecular weight of 382.4 and a molecular formula of C21H18O7. The compound is a natural product isolated from Uvaria grandiflora. Detailed pharmacokinetic data for Zeylenone are not extensively documented in publicly available literature. As a natural product with a cyclohexene oxide structure, its absorption, distribution, metabolism, and excretion properties are subjects of ongoing research. The compound's solubility and stability properties are being studied to support its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for Zeylenone are not extensively documented in publicly available sources. The compound is a natural product intended for research use only and is not approved for human therapeutic applications. Standard laboratory safety practices should be followed when handling this compound, including the use of appropriate personal protective equipment and adherence to institutional biosafety and chemical hygiene guidelines. Further toxicological studies are needed to assess the safety profile of Zeylenone.
|
| References | |
| Additional Infomation |
Reports indicate that methyl benzoate ((1S,5R,6S)-5-(benzoyloxy)-1,6-dihydroxy-2-oxocyclohex-3-en-1-yl)benzoate has been discovered in Uvalia grandiflora, and related data are available.
Zeylenone is a naturally occurring cyclohexene oxide isolated from Uvaria grandiflora that exhibits antitumor and antiproliferative activity. It inhibits cervical cancer cell proliferation and induces apoptosis through the PI3K/AKT/mTOR and MAPK/ERK signaling pathways. Zeylenone also exhibits anti-inflammatory and antioxidant properties. The compound is being studied for its potential therapeutic applications in cancer and inflammatory diseases. Zeylenone is for research purposes only. |
| Molecular Formula |
C21H18O7
|
|---|---|
| Molecular Weight |
382.3634
|
| Exact Mass |
382.105
|
| CAS # |
193410-84-3
|
| PubChem CID |
10571940
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
569.6±50.0 °C at 760 mmHg
|
| Melting Point |
150-152℃
|
| Flash Point |
201.4±23.6 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.642
|
| LogP |
3.78
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
28
|
| Complexity |
616
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1=CC=C(C=C1)C(=O)OC[C@@]2([C@H]([C@@H](C=CC2=O)OC(=O)C3=CC=CC=C3)O)O
|
| InChi Key |
UUNZIGRBVXAOSR-PLMTUMEDSA-N
|
| InChi Code |
InChI=1S/C21H18O7/c22-17-12-11-16(28-20(25)15-9-5-2-6-10-15)18(23)21(17,26)13-27-19(24)14-7-3-1-4-8-14/h1-12,16,18,23,26H,13H2/t16-,18+,21-/m1/s1
|
| Chemical Name |
[(1S,5R,6S)-5-benzoyloxy-1,6-dihydroxy-2-oxocyclohex-3-en-1-yl]methyl benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6153 mL | 13.0767 mL | 26.1534 mL | |
| 5 mM | 0.5231 mL | 2.6153 mL | 5.2307 mL | |
| 10 mM | 0.2615 mL | 1.3077 mL | 2.6153 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
